Key result
CMR feature tracking shows impaired LV GLS of ~-19% in HCM patients versus healthy controls.
Why the study?
CMR feature tracking strain provides prognostic information, but there is a paucity of data in hypertrophic cardiomyopathy.
Does CMR feature tracking strain correlate with circulating cardiac biomarkers (NT-proBNP and hsTnT) in patients with hypertrophic cardiomyopathy?
Population
144 HCM patients and 16 healthy controls
Comparison
HCM patients vs healthy controls, and HCM patients with elevated vs normal NT-proBNP and/or hsTnT
Design
Retrospective study
Authors
Loading...
Identifies subclinical LV dysfunction in HCM despite normal LVEF; leaves open its utility for risk stratification or management.
Case-Control (n=160)
Does CMR feature tracking strain correlate with circulating cardiac biomarkers (NT-proBNP and hsTnT) in patients with hypertrophic cardiomyopathy?
Absolute Event Rate: -18.9% vs -23.5%
p-value: p=0.0001
CMR feature tracking reveals subclinical left ventricular and left atrial dysfunction in HCM patients with normal LVEF, which correlates with elevated cardiac biomarkers.
Çavuş et al. (2021) conducted a case-control in Hypertrophic cardiomyopathy (n=160). CMR feature tracking strain vs. Healthy controls was evaluated on Left ventricular long-axis global longitudinal strain (LVLAX-GLS) (p=0.0001). CMR feature tracking revealed significantly impaired left ventricular global longitudinal strain in hypertrophic cardiomyopathy patients compared to healthy controls (-18.9% vs -23.5%, p=0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: